Wesley C Van Voorhis

List of Publications by Year in Descending Order

113 papers	3,683 citations	34 h-index	57 g-index
123 ext. papers	4,671 ext. citations	7.3 avg, IF	5.21 L-index

#	Paper	IF	Citations
113	Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. **2022**,		2
112	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage.. *Nature Communications*, **2022**, 13, 1976	17.4	3
111	SARS-CoV-2 spike conformation determines plasma neutralizing activity. **2021**,		6
110	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. *Science*, **2021**, eabl8506	33.3	65
109	Pharmacokinetics and pharmacodynamics of clofazimine for treatment of cryptosporidiosis. *Antimicrobial Agents and Chemotherapy*, **2021**, AAC0156021	5.9	1
108	A short-term treatment with BKI-1294 does not protect foetuses from sheep experimentally infected with Neospora caninum tachyzoites during pregnancy. *International Journal for Parasitology: Drugs and Drug Resistance*, **2021**, 17, 176-185	4	0
107	Naegleria fowleri: Protein structures to facilitate drug discovery for the deadly, pathogenic free-living amoeba. *PLoS ONE*, **2021**, 16, e0241738	3.7	4
106	Repurposing Infectious Disease Hits as Anti- Leads. *ACS Infectious Diseases*, **2021**, 7, 1275-1282	5.5	2
105	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines **2021**,		12
104	High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity. *PLoS ONE*, **2021**, 16, e0250019	3.7	10
103	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. *Science*, **2021**, 373, 648-654	33.3	197
102	One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases. *Veterinary Parasitology*, **2021**, 289, 109336	2.8	5
101	Development of a target identification approach using native mass spectrometry. *Scientific Reports*, **2021**, 11, 2387	4.9	7
100	Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis. *ACS Infectious Diseases*, **2021**, 7, 1200-1207	5.5	1
99	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. *Scientific Reports*, **2021**, 11, 4290	4.9	9
98	Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants **2021**,		31
97	In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts. *International Journal for Parasitology: Drugs and Drug Resistance*, **2021**, 16, 90-101	4	3

96	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. *Cell*, **2021**, 184, 5432-5447.e16	56.2	34
95	Endochin-like quinolones (ELQs) and bumped kinase inhibitors (BKIs): Synergistic and additive effects of combined treatments against Neospora caninum infection in vitro and in vivo. *International Journal for Parasitology: Drugs and Drug Resistance*, **2021**, 17, 92-106	4	1
94	: Structure and Fate of Multinucleated Complexes Induced by the Bumped Kinase Inhibitor BKI-1294. *Pathogens*, **2020**, 9,	4.5	6
93	: Differential Proteome of Multinucleated Complexes Induced by the Bumped Kinase Inhibitor BKI-1294. *Microorganisms*, **2020**, 8,	4.9	7
92	Taming the Boys for Global Good: Contraceptive Strategy to Stop Malaria Transmission. *Molecules*, **2020**, 25,	4.8	3
91	Structures of glyceraldehyde 3-phosphate dehydrogenase in Neisseria gonorrhoeae and Chlamydia trachomatis. *Protein Science*, **2020**, 29, 768-778	6.3	6
90	Toward a structome of Acinetobacter baumannii drug targets. *Protein Science*, **2020**, 29, 789-802	6.3	1
89	In Vitro Culture of Cryptosporidium parvum Using Hollow Fiber Bioreactor: Applications for Simultaneous Pharmacokinetic and Pharmacodynamic Evaluation of Test Compounds. *Methods in Molecular Biology*, **2020**, 2052, 335-350	1.4	8
88	Solution structure for an Encephalitozoon cuniculi adrenodoxin-like protein in the oxidized state. *Protein Science*, **2020**, 29, 809-817	6.3	2
87	Reduced treatment frequencies with bumped kinase inhibitor 1369 are effective against porcine cystoisosporosis. *International Journal for Parasitology: Drugs and Drug Resistance*, **2020**, 14, 37-45	4	2
86	Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice. *International Journal of Antimicrobial Agents*, **2020**, 56, 106099	14.3	2
85	Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. *International Journal for Parasitology*, **2020**, 50, 413-422	4.3	21
84	P-Glycoprotein-Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium. *Journal of Infectious Diseases*, **2019**, 220, 1188-1198	7	6
83	Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	13
82	Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. *Journal of Medicinal Chemistry*, **2019**, 62, 3135-3146	8.3	18
81	Bumped kinase inhibitor 1369 is effective against Cystoisospora suis in vivo and in vitro. *International Journal for Parasitology: Drugs and Drug Resistance*, **2019**, 10, 9-19	4	7
80	Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Infection. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	21
79	Enzymatic and Structural Characterization of the Glucokinase. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	10

78	Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis. *Journal of Infectious Diseases*, **2019**, 219, 1464-1473	7	8
77	Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with Neospora caninum tachyzoites. *International Journal for Parasitology: Drugs and Drug Resistance*, **2018**, 8, 112-124	4	17
76	Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	24
75	In vitro growth inhibition of Theileria equi by bumped kinase inhibitors. *Veterinary Parasitology*, **2018**, 251, 90-94	2.8	3
74	Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	11
73	7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors. *ACS Infectious Diseases*, **2018**, 4, 516-522	5.5	5
72	Structure and analysis of nucleoside diphosphate kinase from Borrelia burgdorferi prepared in a transition-state complex with ADP and vanadate moieties. *Acta Crystallographica Section F, Structural Biology Communications*, **2018**, 74, 373-384	1.1	1
71	Extended-spectrum antiprotozoal bumped kinase inhibitors: A review. *Experimental Parasitology*, **2017**, 180, 71-83	2.1	39
70	Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	16
69	Susceptibility Testing of Medically Important Parasites. *Clinical Microbiology Reviews*, **2017**, 30, 647-669	34	5
68	5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	14
67	Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. *Journal of Infectious Diseases*, **2017**, 215, 1275-1284	7	42
66	In vitro efficacy of bumped kinase inhibitors against Besnoitia besnoiti tachyzoites. *International Journal for Parasitology*, **2017**, 47, 811-821	4.3	16
65	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. *International Journal for Parasitology*, **2017**, 47, 753-763	4.3	22
64	Malaria. *Nature Reviews Disease Primers*, **2017**, 3, 17050	51.1	250
63	Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection. *Journal of Infectious Diseases*, **2017**, 216, 55-63	7	34
62	Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase. *ACS Infectious Diseases*, **2017**, 3, 34-44	5.5	28
61	Recombinant human G6PD for quality control and quality assurance of novel point-of-care diagnostics for G6PD deficiency. *PLoS ONE*, **2017**, 12, e0177885	3.7	4

60	Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy. *International Journal for Parasitology*, **2016**, 46, 871-880	4.3	17
59	A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice. *Journal of Infectious Diseases*, **2016**, 214, 1850-1855	7	23
58	Seymour J. Klebanoff: Discoverer of WBC killing mechanisms. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 12891-12892	11.5	
57	5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 5487-5491	2.9	14
56	Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis. *Journal of Medicinal Chemistry*, **2016**, 59, 6531-46	8.3	68
55	Mycobacterium Cytidylate Kinase Appears to Be an Undruggable Target. *Journal of Biomolecular Screening*, **2016**, 21, 695-700		
54	Bumped kinase inhibitor prohibits egression in Babesia bovis. *Veterinary Parasitology*, **2016**, 215, 22-8	2.8	16
53	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. *PLoS ONE*, **2016**, 11, e0149996	3.7	34
52	Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis. *PLoS ONE*, **2016**, 11, e0160350	3.7	13
51	Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. *PLoS Pathogens*, **2016**, 12, e1005763	7.6	167
50	Reduced Activity of Mutant Calcium-Dependent Protein Kinase 1 Is Compensated in Plasmodium falciparum through the Action of Protein Kinase G. *MBio*, **2016**, 7,	7.8	25
49	Optimization of Electrospray Ionization by Statistical Design of Experiments and Response Surface Methodology: Protein-Ligand Equilibrium Dissociation Constant Determinations. *Journal of the American Society for Mass Spectrometry*, **2016**, 27, 1520-30	3.5	17
48	Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis. *Journal of Infectious Diseases*, **2016**, 214, 1856-1864	7	43
47	Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor. *Parasites and Vectors*, **2015**, 8, 33	4	23
46	SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of CDPK1. *ACS Medicinal Chemistry Letters*, **2015**, 6, 1184-1189	4.3	27
45	A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0003987	4.8	32
44	Malaria medicines: a glass half full?. *Nature Reviews Drug Discovery*, **2015**, 14, 424-42	64.1	303
43	The Bacterial Sec Pathway of Protein Export: Screening and Follow-Up. *Journal of Biomolecular Screening*, **2015**, 20, 921-6		1

42	In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6361-74	5.9	47
41	Profile of William C. Campbell, Satoshi Ōmura, and Youyou Tu, 2015 Nobel Laureates in Physiology or Medicine. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15773-6	11.5	22
40	Increasing the structural coverage of tuberculosis drug targets. *Tuberculosis*, **2015**, 95, 142-8	2.6	80
39	Potent and selective inhibitors of CDPK1 from and based on a 5-aminopyrazole-4-carboxamide scaffold. *ACS Medicinal Chemistry Letters*, **2014**, 5, 40-44	4.3	42
38	Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. *European Journal of Medicinal Chemistry*, **2014**, 74, 562-73	6.8	44
37	Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3547-9	5.9	56
36	The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites. *Parasitology*, **2014**, 141, 1499-1509	2.7	40
35	Crystal structure and putative substrate identification for the Entamoeba histolytica low molecular weight tyrosine phosphatase. *Molecular and Biochemical Parasitology*, **2014**, 193, 33-44	1.9	6
34	Neospora caninum calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapy. *PLoS ONE*, **2014**, 9, e92929	3.7	48
33	Calcium-Dependent Protein Kinases of Apicomplexan Parasites as Drug Targets **2013**, 293-316		1
32	Combining functional and structural genomics to sample the essential Burkholderia structome. *PLoS ONE*, **2013**, 8, e53851	3.7	93
31	Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5264-7	2.9	38
30	Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. *Journal of Medicinal Chemistry*, **2012**, 55, 2416-26	8.3	88
29	Stabilizing additives added during cell lysis aid in the solubilization of recombinant proteins. *PLoS ONE*, **2012**, 7, e52482	3.7	57
28	Fragment screening of infectious disease targets in a structural genomics environment. *Methods in Enzymology*, **2011**, 493, 533-56	1.7	5
27	Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. *Molecular and Biochemical Parasitology*, **2011**, 176, 98-108	1.9	32
26	Immobilized metal-affinity chromatography protein-recovery screening is predictive of crystallographic structure success. *Acta Crystallographica Section F: Structural Biology Communications*, **2011**, 67, 998-1005		66
25	High-throughput protein production and purification at the Seattle Structural Genomics Center for Infectious Disease. *Acta Crystallographica Section F: Structural Biology Communications*, **2011**, 67, 1010-4		62

24	Structural genomics of infectious disease drug targets: the SSGCID. *Acta Crystallographica Section F: Structural Biology Communications*, **2011**, 67, 979-84		47
23	An essential farnesylated kinesin in Trypanosoma brucei. *PLoS ONE*, **2011**, 6, e26508	3.7	3
22	Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. *ACS Medicinal Chemistry Letters*, **2010**, 1, 331-335	4.3	110
21	Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. *Nature Structural and Molecular Biology*, **2010**, 17, 602-7	17.6	144
20	Use of thermal melt curves to assess the quality of enzyme preparations. *Analytical Biochemistry*, **2010**, 399, 268-75	3.1	25
19	The role of medical structural genomics in discovering new drugs for infectious diseases. *PLoS Computational Biology*, **2009**, 5, e1000530	5	29
18	Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. *Molecular and Biochemical Parasitology*, **2007**, 152, 66-71	1.9	24
17	Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3659-71	5.9	33
16	Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. *Transfusion*, **2005**, 45, 1459-63	2.9	46
15	Subfamily I Treponema pallidum repeat protein family: sequence variation and immunity. *Microbes and Infection*, **2004**, 6, 725-37	9.3	45
14	Serodiagnosis of syphilis: antibodies to recombinant Tp0453, Tp92, and Gpd proteins are sensitive and specific indicators of infection by Treponema pallidum. *Journal of Clinical Microbiology*, **2003**, 41, 3668-74	9.7	29
13	Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 475-9	5.9	71
12	LYT1 protein is required for efficient in vitro infection by Trypanosoma cruzi. *Infection and Immunity* , **2001**, 69, 3916-23	3.7	50
11	Multiple alleles of Treponema pallidum repeat gene D in Treponema pallidum isolates. *Journal of Bacteriology*, **2000**, 182, 2332-5	3.5	45
10	The tprK gene is heterogeneous among Treponema pallidum strains and has multiple alleles. *Infection and Immunity*, **2000**, 68, 824-31	3.7	75
9	Virulence in Trypanosoma cruzi infection correlates with the expression of a distinct family of sialidase superfamily genes. *Molecular and Biochemical Parasitology*, **1999**, 98, 105-16	1.9	39
8	Sequence conservation of glycerophosphodiester phosphodiesterase among Treponema pallidum strains. *Infection and Immunity*, **1999**, 67, 3168-70	3.7	29
7	T-Cell responses to Treponema pallidum subsp. pallidum antigens during the course of experimental syphilis infection. *Infection and Immunity*, **1999**, 67, 4757-63	3.7	39

6	Function and protective capacity of Treponema pallidum subsp. pallidum glycerophosphodiester phosphodiesterase. *Infection and Immunity*, **1998**, 66, 5763-70	3.7	36
5	Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes. *European Journal of Immunology*, **1997**, 27, 2541-8	6.1	13
4	Trypanosoma cruzi-infected macrophages are defective in major histocompatibility complex class II antigen presentation. *European Journal of Immunology*, **1997**, 27, 3085-94	6.1	30
3	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19		4
2	Naegleria fowleri: protein structures to facilitate drug discovery for the deadly, pathogenic free-living amoeba		1
1	High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity		1